Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis.

Zhang H, Yokom AL, Cheng S, Su M, Hollenberg PF, Southworth DR, Osawa Y.

J Biol Chem. 2018 May 18;293(20):7727-7736. doi: 10.1074/jbc.RA117.000600. Epub 2018 Apr 4.

2.

Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Lin HL, Zhang H, Hollenberg PF.

Drug Metab Dispos. 2018 Jun;46(6):813-822. doi: 10.1124/dmd.118.080903. Epub 2018 Mar 30.

3.

Functional characterization of the G162R and D216H genetic variants of human CYP17A1.

Capper CP, Liu J, McIntosh LR, Larios JM, Johnson MD, Hollenberg PF, Osawa Y, Auchus RJ, Rae JM.

J Steroid Biochem Mol Biol. 2018 Apr;178:159-166. doi: 10.1016/j.jsbmb.2017.12.002. Epub 2017 Dec 9.

4.

Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Lin HL, Zhang H, Walker VJ, D'Agostino J, Hollenberg PF.

Drug Metab Dispos. 2017 Sep;45(9):990-999. doi: 10.1124/dmd.117.075846. Epub 2017 Jul 11.

5.

Enzymology in Chemical Toxicology: Beyond P450s.

Hollenberg PF.

Chem Res Toxicol. 2016 Sep 19;29(9):1365-6. doi: 10.1021/acs.chemrestox.6b00263. No abstract available.

PMID:
27640214
6.
7.

Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis.

Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT.

J Pharmacol Exp Ther. 2016 Oct;359(1):11-7. doi: 10.1124/jpet.116.236034. Epub 2016 Aug 10.

8.

Assay of Endocannabinoid Oxidation by Cytochrome P450.

Snider NT, Walker VJ, Hollenberg PF.

Methods Mol Biol. 2016;1412:227-36. doi: 10.1007/978-1-4939-3539-0_23.

PMID:
27245908
9.

Oxidative hemoglobin reactions: Applications to drug metabolism.

Spolitak T, Hollenberg PF, Ballou DP.

Arch Biochem Biophys. 2016 Jun 15;600:33-46. doi: 10.1016/j.abb.2016.04.007. Epub 2016 Apr 16.

PMID:
27091316
10.

Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.

Walker VJ, Griffin AP, Hammar DK, Hollenberg PF.

J Pharmacol Exp Ther. 2016 Jun;357(3):537-44. doi: 10.1124/jpet.116.232553. Epub 2016 Mar 21.

11.

Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Chlorpyrifos.

D'Agostino J, Zhang H, Kenaan C, Hollenberg PF.

Chem Res Toxicol. 2015 Jul 20;28(7):1484-95. doi: 10.1021/acs.chemrestox.5b00156. Epub 2015 Jun 30.

12.

Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Calinski DM, Zhang H, Ludeman S, Dolan ME, Hollenberg PF.

Drug Metab Dispos. 2015 Jul;43(7):1084-90. doi: 10.1124/dmd.115.063628. Epub 2015 May 1.

13.

Chemical toxicology in China: a special issue.

Zhu BZ, Hollenberg PF.

Chem Res Toxicol. 2015 Mar 16;28(3):279-80. doi: 10.1021/acs.chemrestox.5b00062. No abstract available.

PMID:
25772477
14.

CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel.

Zhang H, Lauver DA, Hollenberg PF.

Thromb Haemost. 2014 Dec;112(6):1304-11. doi: 10.1160/TH14-04-0388. Epub 2014 Sep 18.

PMID:
25230737
15.

The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.

Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg PF.

Drug Metab Dispos. 2013 Oct;41(10):1813-24. doi: 10.1124/dmd.113.053108. Epub 2013 Jul 25.

16.

Role of the highly conserved threonine in cytochrome P450 2E1: prevention of H2O2-induced inactivation during electron transfer.

Yoshigae Y, Kent UM, Hollenberg PF.

Biochemistry. 2013 Jul 9;52(27):4636-47. doi: 10.1021/bi4004843. Epub 2013 Jun 28.

17.

High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators.

Kenaan C, Zhang H, Hollenberg PF.

Methods Mol Biol. 2013;987:61-9. doi: 10.1007/978-1-62703-321-3_5.

PMID:
23475667
18.

The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.

Yoshigae Y, Sridar C, Kent UM, Hollenberg PF.

Drug Metab Dispos. 2013 Apr;41(4):858-69. doi: 10.1124/dmd.112.050609. Epub 2013 Jan 31.

19.

Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.

Zhang H, Lauver DA, Lucchesi BR, Hollenberg PF.

Mol Pharmacol. 2013 Apr;83(4):848-56. doi: 10.1124/mol.112.084392. Epub 2013 Jan 24.

20.

Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis.

Zhang H, Gay SC, Shah M, Foroozesh M, Liu J, Osawa Y, Zhang Q, Stout CD, Halpert JR, Hollenberg PF.

Biochemistry. 2013 Jan 15;52(2):355-64. doi: 10.1021/bi301567z. Epub 2013 Jan 4.

21.

Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism.

Kenaan C, Shea EV, Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF.

Drug Metab Dispos. 2013 Jan;41(1):101-10. doi: 10.1124/dmd.112.046094. Epub 2012 Oct 5.

22.

Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase.

Lin HL, Kenaan C, Zhang H, Hollenberg PF.

Chem Res Toxicol. 2012 Dec 17;25(12):2642-53. doi: 10.1021/tx3002753. Epub 2012 Oct 16.

23.

Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches.

Sridar C, Hanna I, Hollenberg PF.

Xenobiotica. 2013 Apr;43(4):336-45. doi: 10.3109/00498254.2012.719089. Epub 2012 Sep 3.

PMID:
22943130
24.

Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein.

Sridar C, D'Agostino J, Hollenberg PF.

Drug Metab Dispos. 2012 Dec;40(12):2280-8. doi: 10.1124/dmd.112.047266. Epub 2012 Aug 31.

25.

Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.

Sridar C, Kenaan C, Hollenberg PF.

Drug Metab Dispos. 2012 Dec;40(12):2256-66. doi: 10.1124/dmd.112.046979. Epub 2012 Aug 30.

26.

Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH.

Drug Metab Dispos. 2012 Nov;40(11):2174-84. doi: 10.1124/dmd.112.047530. Epub 2012 Aug 17.

27.

Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme.

Amunugama HT, Zhang H, Hollenberg PF.

Drug Metab Dispos. 2012 Sep;40(9):1765-70. doi: 10.1124/dmd.112.045971. Epub 2012 Jun 8.

28.

Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.

Zhang H, Lau WC, Hollenberg PF.

Mol Pharmacol. 2012 Aug;82(2):302-9. doi: 10.1124/mol.112.079061. Epub 2012 May 14.

29.

Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Lin HL, Kenaan C, Hollenberg PF.

Drug Metab Dispos. 2012 May;40(5):998-1006. doi: 10.1124/dmd.112.044560. Epub 2012 Feb 16.

30.

Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF.

Drug Metab Dispos. 2011 Dec;39(12):2431-9. doi: 10.1124/dmd.111.042176. Epub 2011 Sep 19.

31.

Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.

Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF.

Mol Pharmacol. 2011 Nov;80(5):839-47. doi: 10.1124/mol.111.073783. Epub 2011 Aug 23.

32.
33.

Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods VL Jr, Stout CD, Hollenberg PF, Halpert JR.

Biochemistry. 2011 Jun 7;50(22):4903-11. doi: 10.1021/bi200482g. Epub 2011 May 13.

34.

Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions.

Kenaan C, Zhang H, Shea EV, Hollenberg PF.

Biochemistry. 2011 May 17;50(19):3957-67. doi: 10.1021/bi1020748. Epub 2011 Apr 22.

35.

Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Sridar C, Snider NT, Hollenberg PF.

Drug Metab Dispos. 2011 May;39(5):782-8. doi: 10.1124/dmd.110.036707. Epub 2011 Feb 2.

36.

Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.

Lin HL, Zhang H, Medower C, Hollenberg PF, Johnson WW.

Drug Metab Dispos. 2011 Feb;39(2):345-50. doi: 10.1124/dmd.110.034074. Epub 2010 Nov 10.

37.

A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6.

Kenaan C, Zhang H, Hollenberg PF.

Nat Protoc. 2010 Sep;5(10):1652-8. doi: 10.1038/nprot.2010.125. Epub 2010 Sep 23.

38.

Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes.

Zhang H, Lin HL, Kenaan C, Hollenberg PF.

Arch Biochem Biophys. 2011 Mar 1;507(1):135-43. doi: 10.1016/j.abb.2010.09.006. Epub 2010 Sep 15. Review.

39.

Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate.

Pratt-Hyatt M, Lin HL, Hollenberg PF.

Drug Metab Dispos. 2010 Dec;38(12):2286-92. doi: 10.1124/dmd.110.034710. Epub 2010 Sep 8.

40.

Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide.

Pratt-Hyatt M, Zhang H, Snider NT, Hollenberg PF.

Drug Metab Dispos. 2010 Nov;38(11):2075-82. doi: 10.1124/dmd.110.033712. Epub 2010 Aug 11.

41.

Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Lin HL, Zhang H, Jushchyshyn M, Hollenberg PF.

J Pharmacol Exp Ther. 2010 Jun;333(3):663-9. doi: 10.1124/jpet.109.164350. Epub 2010 Mar 3.

42.

Beta sheet 2-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners.

Jang HH, Jamakhandi AP, Sullivan SZ, Yun CH, Hollenberg PF, Miller GP.

Biochim Biophys Acta. 2010 Jun;1804(6):1285-93. doi: 10.1016/j.bbapap.2010.02.003. Epub 2010 Feb 10.

43.

Introduction: mechanisms of metal toxicity special issue.

Hollenberg PF.

Chem Res Toxicol. 2010 Feb 15;23(2):292-3. doi: 10.1021/tx900456p. No abstract available.

PMID:
20151720
44.

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Snider NT, Walker VJ, Hollenberg PF.

Pharmacol Rev. 2010 Mar;62(1):136-54. doi: 10.1124/pr.109.001081. Epub 2010 Feb 4. Review.

45.

Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: Identification of a potential site of interaction.

Bumpus NN, Hollenberg PF.

J Inorg Biochem. 2010 Apr;104(4):485-8. doi: 10.1016/j.jinorgbio.2009.12.017. Epub 2010 Jan 4.

46.

Defining the structural consequences of mechanism-based inactivation of mammalian cytochrome P450 2B4 using resonance Raman spectroscopy.

Mak PJ, Zhang H, Hollenberg PF, Kincaid JR.

J Am Chem Soc. 2010 Feb 10;132(5):1494-5. doi: 10.1021/ja910276s.

47.

Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress.

Hanada S, Snider NT, Brunt EM, Hollenberg PF, Omary MB.

Gastroenterology. 2010 Apr;138(4):1607-17. doi: 10.1053/j.gastro.2009.12.055. Epub 2010 Jan 11.

48.

tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.

Zhang H, Lin HL, Walker VJ, Hamdane D, Hollenberg PF.

Mol Pharmacol. 2009 Nov;76(5):1011-8. doi: 10.1124/mol.109.059808. Epub 2009 Aug 31.

49.

Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Lin HL, Zhang H, Noon KR, Hollenberg PF.

J Pharmacol Exp Ther. 2009 Nov;331(2):392-403. doi: 10.1124/jpet.109.158782. Epub 2009 Aug 21.

50.

Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1.

Zhang H, Kenaan C, Hamdane D, Hoa GH, Hollenberg PF.

J Biol Chem. 2009 Sep 18;284(38):25678-86. doi: 10.1074/jbc.M109.032748. Epub 2009 Jul 15.

Supplemental Content

Loading ...
Support Center